Literature DB >> 17562178

A comparison of risk factors for HCV-mono-infection, HIV-mono-infection, and HCV/HIV-co-infection in a community setting.

Srigayatri Bollepalli1, Kathleen Mathieson, Beata Jasiurkowski, Amy Hillier, John Post, Shakil Bhanu, Dean Martin, David H Van Thiel, Abdul Nadir.   

Abstract

The prevalence of HIV infection in HCV patients is much lower than the prevalence of HCV infection in HIV patients. Whereas the higher prevalence of HCV infection in HIV is clearly related to drug abuse, the reasons for the lower prevalence of HIV infection in HCV patients has not been reported. The prevalence of non-sexual and sexual risk factors associated with acquisition of hepatitis C and HIV were studied in HIV-mono-infected, HCV-mono-infected, and HCV/HIV-co-infected individuals. None of the 114 HCV-mono-infected patients tested positive for HIV and this finding was associated with a significantly lower number of men who have sex with men (MSM) among the HCV-mono-infected subjects than among either the HIV-mono-infected or HCV/HIV-co-infected individuals. Unprotected anal intercourse and sex for money or drugs were reported less often by HCV-mono-infected individuals than by HIV-mono-infected and HCV/HIV-co-infected subjects. Having sex with an intravenous-drug user (IVDU) was reported more frequently by both HCV-mono-infected and HCV/HIV-co-infected individuals than by HIV-mono-infected individuals. Sub-analysis of the group of MSM revealed that IVDU differentiated between HIV-mono-infected and HCV/HIV-co-infected subjects. These results reveal that the lower prevalence of HIV in HCV patients is related to a lower number of MSM in this group and that sex with an IVDU is a surrogate marker for drug abuse related to acquiring HCV but not HIV. The guidelines should include strategies for testing for HCV and HIV in patients with these infections.

Entities:  

Mesh:

Year:  2007        PMID: 17562178     DOI: 10.1007/s10620-007-9856-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

1.  Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS)

Authors:  E L Murphy; S M Bryzman; S A Glynn; D I Ameti; R A Thomson; A E Williams; C C Nass; H E Ownby; G B Schreiber; F Kong; K R Neal; G J Nemo
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

2.  Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men.

Authors:  Michel Alary; Jean R Joly; Jean Vincelette; René Lavoie; Bruno Turmel; Robert S Remis
Journal:  Am J Public Health       Date:  2005-03       Impact factor: 9.308

3.  Integrated hepatitis C virus treatment: addressing comorbid substance use disorders and HIV infection.

Authors:  Marilyn S Huckans; Aaron D Blackwell; Todd A Harms; David W Indest; Peter Hauser
Journal:  AIDS       Date:  2005-10       Impact factor: 4.177

4.  Odds ratio or relative risk for cross-sectional data?

Authors:  J Lee
Journal:  Int J Epidemiol       Date:  1994-02       Impact factor: 7.196

5.  [Sexual transmission of hepatitis C in homosexual men].

Authors:  Th A Ruys; J G den Hollander; M G H M Beld; M E van der Ende; J T M van der Meer
Journal:  Ned Tijdschr Geneeskd       Date:  2004-11-20

6.  Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case. A multicentre study of 423 pairings.

Authors:  B Soto; L Rodrigo; M Garcia-Bengoechea; A Sanchez-Quijano; S Riestra; J I Arenas; J Andreu; M Rodriguez; J I Emparanza; Y Torres
Journal:  J Intern Med       Date:  1994-11       Impact factor: 8.989

Review 7.  Hepatitis C in the HIV-Infected Person.

Authors:  Mark S Sulkowski; David L Thomas
Journal:  Ann Intern Med       Date:  2003-02-04       Impact factor: 25.391

8.  Acute hepatitis C in HIV-infected men who have sex with men.

Authors:  J Ghosn; S Pierre-François; V Thibault; C Duvivier; R Tubiana; A Simon; M A Valantin; S Dominguez; E Caumes; C Katlama
Journal:  HIV Med       Date:  2004-07       Impact factor: 3.180

9.  Prevalence of human immunodeficiency virus testing in patients with hepatitis B and C infection.

Authors:  Alysa Krain; Juan P Wisnivesky; Elizabeth Garland; Thomas McGinn
Journal:  Mayo Clin Proc       Date:  2004-01       Impact factor: 7.616

10.  Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio.

Authors:  Aluísio J D Barros; Vânia N Hirakata
Journal:  BMC Med Res Methodol       Date:  2003-10-20       Impact factor: 4.615

View more
  5 in total

1.  Optimizing hepatitis C therapy in HIV/hepatitis C virus (HCV) coinfected patients: Analysis of HCV viral kinetics on treatment.

Authors:  Paul Damien James; David Kh Wong
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

2.  HIV and viral hepatitis co-infection in New York City, 2000-2010: prevalence and case characteristics.

Authors:  C Prussing; C Chan; J Pinchoff; L Kersanske; K Bornschlegel; S Balter; A Drobnik; J Fuld
Journal:  Epidemiol Infect       Date:  2014-08-29       Impact factor: 4.434

3.  Sexual Transmission of Hepatitis C Virus Between HIV Infected Subjects and Their Main Heterosexual Partners.

Authors:  Abbas Alipour; Abbas Rezaianzadeh; Jafar Hasanzadeh; Abdorreza Rajaeefard; Mohammad Ali Davarpanah
Journal:  Hepat Mon       Date:  2013-11-05       Impact factor: 0.660

4.  Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis.

Authors:  Lize Cuypers; Ana Belén Pérez; Natalia Chueca; Teresa Aldamiz-Echevarría; Juan Carlos Alados; Ana María Martínez-Sapiña; Dolores Merino; Juan Antonio Pineda; Francisco Téllez; Nuria Espinosa; Javier Salméron; Antonio Rivero-Juarez; María Jesús Vivancos; Víctor Hontañón; Anne-Mieke Vandamme; Féderico García
Journal:  PLoS One       Date:  2018-07-25       Impact factor: 3.240

5.  HCV/HIV coinfection among people who inject drugs and enter opioid substitution treatment in Greece: prevalence and correlates.

Authors:  Anastasios Fotiou; Eleftheria Kanavou; Argyro Antaraki; Clive Richardson; Manina Terzidou; Anna Kokkevi
Journal:  Hepatol Med Policy       Date:  2016-08-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.